Head and neck cancer, the fifth most common cancer based on MOHW 2011 report in Taiwan, has suboptimal treatment response rates. Recently literatures suggest that Neurotensin receptor 1 plays a very important role in cancer progression and overall survival of patients. To provide a novel therapeutic modality for cancer therapy, DCB and NHRI have developed an anti NTSR1 antibody drug conjugate DCBAD2301 with high specificity, potent tumor suppression, favorable PK, and low toxicity in vitro and in vivo. With a high-yield CHO cell line, DCBAD2301 offers innovative potential for cancer therapy.